Sero-epidemiological Study of the SARS-CoV-2 Virus Responsible for COVID-19 in France

CompletedOBSERVATIONAL
Enrollment

5,000

Participants

Timeline

Start Date

March 13, 2020

Primary Completion Date

May 31, 2023

Study Completion Date

May 31, 2023

Conditions
SARS (Severe Acute Respiratory Syndrome)COVID-19
Interventions
OTHER

Human Biological samples

Blood samples for serological tests

OTHER

Human Biological samples

Blood samples, saliva, nasopharyngeal swab for serological tests

Trial Locations (21)

75014

Institut Mutualiste, Paris

75015

Centre Médical de l'Institut Pasteur, Paris

Institut Pasteur, Paris

Unknown

CHU Amiens-Picardie, Amiens

EHPAD Villa Concorde, Asnières-sur-Seine

CHU François Mitterand, Dijon

Centre Hospitalier Départemental de Vendée, La Roche-sur-Yon

CHU Limoges, Limoges

Hôpital de la Croix Rousse, Lyon

EHPAD Les Etangs, Mennecy

CHRU de Nancy, Nancy

Hôpitaux de Brabois, Nancy

CHR Orléans, Orléans

EHPAD Villa Lecourbe, Paris

Hôpital la Pitié Salpetrière, Paris

CHU Poitiers, Poitiers

Hôpital Pontchaillou, Rennes

CHU Saint-Etienne, Saint-Etienne

CHRU de Strasbourg, Strasbourg

CH de Tourcoing, Tourcoing

Hôpital Bretonneau, Tours

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Institut Pasteur

INDUSTRY

NCT04325646 - Sero-epidemiological Study of the SARS-CoV-2 Virus Responsible for COVID-19 in France | Biotech Hunter | Biotech Hunter